Cargando…
Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
A wide range of sleep dysfunction complicates Parkinson’s disease during its course from prodromal to palliative stage. It is now increasingly acknowledged that sleep disturbances are thus integral to the disease and pose a significant burden impacting on quality of life of patients. Sleep fragmenta...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585311/ https://www.ncbi.nlm.nih.gov/pubmed/28890931 http://dx.doi.org/10.1038/s41531-017-0030-4 |
_version_ | 1783261596433252352 |
---|---|
author | Rosa-Grilo, Miguel Qamar, Mubasher A. Taddei, Raquel N. Pagonabarraga, Javier Kulisevsky, Jaime Sauerbier, Anna Chaudhuri, K. Ray |
author_facet | Rosa-Grilo, Miguel Qamar, Mubasher A. Taddei, Raquel N. Pagonabarraga, Javier Kulisevsky, Jaime Sauerbier, Anna Chaudhuri, K. Ray |
author_sort | Rosa-Grilo, Miguel |
collection | PubMed |
description | A wide range of sleep dysfunction complicates Parkinson’s disease during its course from prodromal to palliative stage. It is now increasingly acknowledged that sleep disturbances are thus integral to the disease and pose a significant burden impacting on quality of life of patients. Sleep fragmentation, restless legs syndrome, nocturia, and nocturnal pain are regarded as one of the main components of night-time sleep dysfunction with possible secondary impact on cognition and well-being. The role of dopaminergic therapies, particularly using a continuous drug delivery strategy in managing some of these sleep issues, have been reported but the overall concept remains unclear. This review provides an overview of several aspects of night-time sleep dysfunction in Parkinson’s disease and describes all available published open-label and blinded studies that investigated the use of rotigotine transdermal patch targeting sleep. Blinded studies have suggested beneficial effects of rotigotine transdermal patch on maintenance insomnia and restless legs syndrome in Parkinson’s disease patients. Open-label studies support these observations and also suggest beneficial effects on nocturia and nocturnal pain. |
format | Online Article Text |
id | pubmed-5585311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55853112017-09-08 Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? Rosa-Grilo, Miguel Qamar, Mubasher A. Taddei, Raquel N. Pagonabarraga, Javier Kulisevsky, Jaime Sauerbier, Anna Chaudhuri, K. Ray NPJ Parkinsons Dis Review Article A wide range of sleep dysfunction complicates Parkinson’s disease during its course from prodromal to palliative stage. It is now increasingly acknowledged that sleep disturbances are thus integral to the disease and pose a significant burden impacting on quality of life of patients. Sleep fragmentation, restless legs syndrome, nocturia, and nocturnal pain are regarded as one of the main components of night-time sleep dysfunction with possible secondary impact on cognition and well-being. The role of dopaminergic therapies, particularly using a continuous drug delivery strategy in managing some of these sleep issues, have been reported but the overall concept remains unclear. This review provides an overview of several aspects of night-time sleep dysfunction in Parkinson’s disease and describes all available published open-label and blinded studies that investigated the use of rotigotine transdermal patch targeting sleep. Blinded studies have suggested beneficial effects of rotigotine transdermal patch on maintenance insomnia and restless legs syndrome in Parkinson’s disease patients. Open-label studies support these observations and also suggest beneficial effects on nocturia and nocturnal pain. Nature Publishing Group UK 2017-09-05 /pmc/articles/PMC5585311/ /pubmed/28890931 http://dx.doi.org/10.1038/s41531-017-0030-4 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Rosa-Grilo, Miguel Qamar, Mubasher A. Taddei, Raquel N. Pagonabarraga, Javier Kulisevsky, Jaime Sauerbier, Anna Chaudhuri, K. Ray Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? |
title | Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? |
title_full | Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? |
title_fullStr | Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? |
title_full_unstemmed | Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? |
title_short | Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? |
title_sort | rotigotine transdermal patch and sleep in parkinson’s disease: where are we now? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585311/ https://www.ncbi.nlm.nih.gov/pubmed/28890931 http://dx.doi.org/10.1038/s41531-017-0030-4 |
work_keys_str_mv | AT rosagrilomiguel rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow AT qamarmubashera rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow AT taddeiraqueln rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow AT pagonabarragajavier rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow AT kulisevskyjaime rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow AT sauerbieranna rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow AT chaudhurikray rotigotinetransdermalpatchandsleepinparkinsonsdiseasewherearewenow |